Hims & Hers Health Inc

Hims & Hers Health Inc(HIMS)の株式分析

$28.840

-2.570 (-8.91%)終値時点

Loading chart…
High
31.400
Open
31.360
VWAP
29.59
Vol
14.73M
Mkt Cap
4.30B
Low
28.520
Amount
435.70M
EV/EBITDA, TTM
-18.79

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.

AI analysis of Hims & Hers Health Inc (HIMS)

sell

Hims & Hers Health Inc is not a good buy right now due to significant risks overshadowing its potential. The current price is $28.84, and the stock has dropped 14.62% over the past five days, indicating negative momentum. Additionally, the RSI is at 40.773, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The company is facing serious legal challenges, including a lawsuit from the FTC and scrutiny from Visa, which could further impact its reputation and financial stability. The forward P/E ratio is high at 58.82, indicating that the stock is overvalued relative to its earnings potential, and the gross margin has decreased to 63.83%, reflecting declining profitability. The main risk is the ongoing FTC investigation, which could lead to further financial penalties and loss of customer trust, potentially driving the stock price lower.

バリュエーション指標

The current forward P/E ratio for Hims & Hers Health Inc (HIMS) is 58.82, compared to its 5-year average forward P/E of 15.43.

Forward P/E

Fair
5Y Average P/E
15.43
Current P/E
58.82
割高
72.91
割安
-42.05

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.27
Current EV/EBITDA
-18.79
割高
46.37
割安
-19.83

Forward P/S

Fair
5Y Average P/S
2.59
Current P/S
1.75
割高
3.75
割安
1.43

Alphio AI Price Scenarios for HIMS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HIMS

$133.17

シナリオ価格

B

Base

Base · 50%HIMS

$111.56

シナリオ価格

B

Bear

Bear · 25%HIMS

$85.01

シナリオ価格

Whales holding HIMS

D

Divisadero Street Capital Management, LP

+ HoldingHIMS

+7.83%

3M Return

S

Summit Trail Advisors, LLC

+ HoldingHIMS

-3.06%

3M Return

H

HANSAINVEST Hanseatische Investment-GmbH

+ HoldingHIMS

-29.13%

3M Return

イベントタイムライン

2026-08-27 (ET)

12:00:00

Hims and Hers Health Shares Rise 3.74%

2026-08-24 (ET)

16:30:00

Nvidia Informs Customers of 15% Price Increase for AI Servers

12:00:00

Nasdaq and S&P 500 Decline as Nvidia Faces Price Hike

11:00:00

Hims & Hers Placed in Visa's Monitoring Program

2026-08-11 (ET)

12:00:00

Major Averages Dip Slightly as Investors Await CPI Report

ニュース

HIMS FAQ — answered by Alphio AI

Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Hims & Hers Health Inc is not a good buy right now due to significant risks overshadowing its potential. The current price is $28.84, and the stock has dropped 14.62% over the past five days, indicating negative momentum. Additionally, the RSI is at 40.773, suggesting the stock is nearing oversold territory but not yet a strong buy signal. The company is facing serious legal challenges, including a lawsuit from the FTC and scrutiny from Visa, which could further impact its reputation and financial stability. The forward P/E ratio is high at 58.82, indicating that the stock is overvalued relative to its earnings potential, and the gross margin has decreased to 63.83%, reflecting declining profitability. The main risk is the ongoing FTC investigation, which could lead to further financial penalties and loss of customer trust, potentially driving the stock price lower.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める